Literature DB >> 2214545

New active analogues of vitamin D with low calcemic activity.

A J Brown1, J L Finch, S Lopez-Hilker, A Dusso, C Ritter, N Pernalete, E Slatopolsky.   

Abstract

In conclusion, a number vitamin D analogues have been developed that have very low calcemic activity but retain several other properties of 1,25-(OH)2D3, including the ability to differentiate leukemia and skin cells, to enhance the immune response, and to suppress parathyroid hormone levels. Although the mechanism of this selective activity is not yet clear, these analogues may provide new insights into the differences in action of 1,25-(OH)2D3 in various target tissues. Most importantly, the selective action of these analogues may be exploited for the treatment of diseases such as leukemia, psoriasis and hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214545

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  3 in total

1.  Calcitriol oral pulse therapy in children with renal osteodystrophy.

Authors:  F Cano; A Delucchi; E Wolff; E Rodriguez; A Fuentes
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

2.  The in vivo effect of a new, in vitro, extremely potent vitamin D3 analog KH1060 on the suppression of renal allograft rejection in the rat.

Authors:  E Lewin; K Olgaard
Journal:  Calcif Tissue Int       Date:  1994-02       Impact factor: 4.333

3.  Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4.

Authors:  P C Dheerendra; V Sakhuja; H S Kohli; V Jha
Journal:  Indian J Nephrol       Date:  2013-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.